Company news
Xilio Therapeutics, Inc. news in 2023
Xilio Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
December 6, 2023
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
November 8, 2023
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
November 2, 2023
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 26, 2023
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
September 4, 2023
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
August 13, 2023
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
August 2, 2023
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
May 24, 2023
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
May 8, 2023
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
March 1, 2023
Decks in 2023
- Q2 2023 Earnings Presentation
Earnings · 52 slides · Aug 14, 2023
- Corporate Update (May 2023)
Corporate update · 54 slides · May 25, 2023
- Investor Presentation (January 2023)
Investor deck · 39 slides · Jan 9, 2023